Hong Kong's struggles with IP valuation revealed
IP valuation expertise lags behind growth of biotech listings in Hong Kong, creating a value gap at the heart of the system
To attract more biotech companies to have initial public offerings in Hong Kong, a new listing regime for biotechs that have yet to make profit was launched in 2018. Since last year, a number of Chinese companies have made Hong...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.